Zilebesiran

Alnylam Pharmaceuticals announces strategic expansion of its late-stage pipeline with three new Phase III trials planned for 2025, demonstrating continued momentum in RNAi therapeutics.

Alnylam showcased multiple potential blockbuster therapies in ATTR amyloidosis, cardiovascular disease, and neuroscience, including the TRITON Phase 3 program for nucresiran, which offers greater than 95% TTR knockdown with twice-annual dosing.

Alnylam's zilebesiran, an RNAi therapy for hypertension, has been granted an Innovation Passport by the UK's MHRA to expedite NHS access.

Alnylam anticipates FDA approval for vutrisiran to treat ATTR amyloidosis with cardiomyopathy by March 23, 2025, and aims for EU and Japan approvals later in the year.

Alnylam forecasts 2025 net product revenues between $2.05 billion and $2.25 billion, a 31% increase from 2024, driven by its TTR and rare disease franchises.